Abstract
I was very concerned to read Dr Burls' remarks on the NICE ruling on riluzole. NICE chief executive Andrew Dillon, in his ruling on the efficacy of the treatment, described the drug as 'clinically effective and cost-effective'. But Dr Burls said [illegible word] the NICE ruling was 'not a reflection of the evidence base' (News February 14).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callSimilar Papers
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
